BioSpace News Archive

A report from the Kaiser Family Foundation estimates that the FDA’s recent approval of Novo Nordisk’s Wegovy to reduce the risk of heart attack and stroke in people with cardiovascular disease will open Medicare coverage to one in four beneficiaries with obesity.

Xaira Therapeutics emerged from stealth on Tuesday with plans to tap the biological equivalent of artificial intelligence image generation tools designed to create molecules that hit hard-to-drug targets.

An undisclosed once-daily oral dose of Neurocrine Biosciences’ Takeda-partnered investigational drug significantly reduced symptom severity in adults with major depressive disorder.

Here’s how to assess whether to develop a new therapy by building a proprietary platform, acquiring another company or asset or partnering with an established entity.

Pharming Group N.V. is pleased to announce its recognition as an Industry Innovator by the National Organization for Rare Disorders at the Rare Impact Awards on June 8, 2024.

Nicox SA informs its shareholders that the Ordinary and Extraordinary General Meeting, having been unable to deliberate on April 10, 2024 as the quorum required by law has not been reached, will be held, on second convening, on Monday May 6, 2024 at 2:30 p.m., at the offices of BuroClub - Drakkar 2 Bâtiment D - 2405 route des Dolines - 06560 Valbonne Sophia Antipolis.

Kuros Biosciences, a leader in advanced bone healing technologies, announced its financial performance for the first quarter of 2024.

Evotec SE reported financial results and corporate updates for the fiscal year ended 31 December 2023 and announced a priority reset to optimise its business to meet evolving market demand and focus on profitable growth in 2024 and beyond.

AAVantgarde Bio announces the publication of an abstract submitted to The Association for Research in Vision and Ophthalmology Annual Meeting, to be held May 5-9 in Seattle.

ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumour cell solutions for use in research, drug development and clinical oncology has signed a supplier agreement with the global biopharmaceutical company, AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE’s existing DNA damage response assay for the detection of micronuclei in CTCs as a measure of DDR.